Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Tilray to Collaborate With Sandoz on Medical Cannabis Products Across the World

By Mike Botta | December 18, 2018

Tilray Inc. announced Tuesday that its Tilray Canada Ltd. subsidiary has entered into a global “framework agreement” to collaborate with Sandoz AG, part of Novartis group, to increase availability of high quality medical cannabis products across the world.

Shares of Tilray were surging in Tuesday afternoon trading after the announcement.

Under the deal, Tilray and Sandoz’s Canadian arm plan to jointly operate in jurisdictions where cannabis is or will be approved for medical purposes.

The agreement, which builds upon an existing alliance between the two companies, also allows the companies to potentially collaborate in such areas as co-branding certain non-smokable/non-combustible products and developing new medical cannabis products.

Tilray was the first licensed medical cannabis producer in North America to obtain current Good Manufacturing Practice (cGMP) certification in accordance with the European Medicines Agency’s (EMA) standards.

Under the framework agreement: 

  • Sandoz AG may support the global commercialization of Tilray’s non-smokable/non-combustible medical cannabis products

  • Tilray and Sandoz AG may co-brand certain non-smokable/non-combustible products

  • Tilray may supply non-smokable/non-combustible medical cannabis products and license rights to and from Sandoz AG in relation to such products; both companies also may partner to leverage best-in-class knowledge to educate pharmacists and physicians about medical cannabis products

  • Tilray and Sandoz AG may collaborate to develop new medical cannabis products.

Tilray’s stock jumped more than 15 percent to $76.05 in afternoon trading Tuesday, while Novartis AG shares dipped 25 cents to $85.51.

The company’s operation in Nanaimo, BC, is licenced to produce dried cannabis and cannabis extracts, including both bottled oil and capsules, for medical purposes, according to Canada’s CTV News. It also has a licenced facility in Enniskillen, ON, and is seeking a licence for a processing facility in London, ON.

Tilray has products available in 12 countries and operations in Australia, New Zealand, Canada, Germany, Latin America, and Portugal.

(Source: Tilray Inc.; Associated Press; CTV News)

Related Articles Read More >

This is the logo of Novartis.
Novartis breaks ground on North Carolina facility
AstraZeneca
AstraZeneca to invest $2B in Maryland, support 2,600 jobs
This is the logo of Novartis.
Novartis opens new manufacturing plant in California
samsung biologics (1)
Samsung Biologics completes Bioepis spinoff to become pure-play pharma CDMO
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE